A Study Of Poly (ADP-Ribose) Polymerase Inhibitor PF-01367338 In Combination With Several Chemotherapeutic Regimens
Dose escalation phase 1 study of PARP inhibitor PF-01367338 in combination with chemotherapy in adult patients with advanced solid tumors
Advanced Solid Tumors
DRUG: PF-01367338|DRUG: Carboplatin|DRUG: PF-01367338|DRUG: Carboplatin
Safety and tolerability of escalating doses of PF-01367338 in combination with chemotherapy (as defined by first-cycle DLTs), Dose-limiting toxicities and adverse events, 18 months
Pharmacokinetics and pharmacodynamics of escalating doses of PF-01367338 in combination with several chemotherapeutic regimens, Time to attain maximum plasma concentration \[Tmax\], 18 months|Pharmacokinetics and pharmacodynamics of escalating doses of PF-01367338 in combination with several chemotherapeutic regimens, maximum plasma concentration (CMax), 18 months|Pharmacokinetics and pharmacodynamics of escalating doses of PF-01367338 in combination with several chemotherapeutic regimens, area under plasma concentration curve (AUC), 18 months|Pharmacokinetics and pharmacodynamics of escalating doses of PF-01367338 in combination with several chemotherapeutic regimens, apparent terminal half-life (t1/2), 18 months|Pharmacokinetics and pharmacodynamics of escalating doses of PF-01367338 in combination with several chemotherapeutic regimens, rucaparib oral bioavailability, 18 months|PARP activity and expression in peripheral blood lymphocytes (PBL), % PARP activity, 18 months|Determination of food effect on oral PF-01367338 pharmacokinetics, fasted and fed parameters area under the plasma concentration-time curve from time 0 to the last recorded observation \[AUClast\], 18 month|Determination of food effect on oral PF-01367338 pharmacokinetics, fasted and fed maximum plasma concentration (Cmax), 18 month|Determination of effect of PF-013567338 administration on QTc prolongation test, electrocardiogram\[ecg\], QTcF, QTcB, 18 months
Dose escalation phase 1 study of PARP inhibitor PF-01367338 in combination with chemotherapy in adult patients with advanced solid tumors